Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg study

Study identifier:D1441C09907

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Quetiapine augmentation to SRIs for patients with obsessive compulsive disorder, a double-blind, placebo-controlled study

Medical condition

Obsessive Compulsive Disorder

Phase

Phase 2

Healthy volunteers

No

Study drug

Quetiapine

Sex

All

Actual Enrollment

90

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Dec 2003
Primary Completion Date: -
Study Completion Date: 01 Aug 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria